Leave message
Can’t find what you’re looking for?
Fill out this form to inquire about our customタンパク質 services!
カスタムサービスについてのお問い合わせはこちら >>
Limited Edition Golden Llama is here! Check out how you can get one. 
Limited Edition Golden Llama is here! Check out how you can get one.
Offering SPR-BLI Services - Proteins provided for free! Offering SPR-BLI Services - Proteins provided for free!
Thank you for choosing ACROBiosystems. Would you rate our product and service？ Thank you for choosing ACROBiosystems. Would you rate our product and service？
Here come GMP Grade Cytokines！Free Sample is available！ Here come GMP Grade Cytokines！Free Sample is available！
| Project Name | Project Stage | Molecule Type | Host Species | Therapeutic Area | Indications |
| Trop2 ADC -01 | IND | Solid Tumor | Non-small cell lung cancer,Pancreatic cancer |
| Project Name | Modality | Therapeutic Area | Indications | Stage | Right Available |
| Trop2 ADC | Bioconjugates | Oncology/Cancer | Gastric cancer,Pancreatic cancer | IND | Global |
Immobilized Mouse Monoclonal Antibody Against Human TROP-2 Protein,Mouse IgG1 at 1 μg/mL (100 μL/well) can bind Biotinylated Cynomolgus TROP-2 Protein, His,Avitag (Cat. No. TR2-C82E3) with a linear range of 5-39 ng/mL (QC tested).
The purity of Cynomolgus TROP-2 Protein, His Tag (Cat. No. TR2-C52H5) is more than 90% and the molecular weight of this protein is around 30-45 kDa verified by SEC-MALS.
| Name | Research Code | Research Phase | Company | First Brand Name | First Approved Country | First Indication | First Approved Company | First Approved Date | Indications | Clinical Trials |
|---|---|---|---|---|---|---|---|---|---|---|
| Sacituzumab govitecan | IMMU-132; TROP-2-SN-38; IMMU0132; GS-0132 | Approved | Immunomedics Inc | Trodelvy, 拓达维 | Mainland China | Triple Negative Breast Neoplasms | Everest Medicines (Suzhou) Inc | 2020-04-22 | Small Cell Lung Carcinoma; Uterine Cervical Neoplasms; Carcinoma, Hepatocellular; Carcinoma, Non-Small-Cell Lung; Brain metastases; Metastatic breast cancer; Endometrial Neoplasms; Prostatic Neoplasms; Breast Neoplasms; Urinary Bladder Neoplasms; Carcinoma, Ovarian Epithelial; Pancreatic Neoplasms; Solid tumours; Carcinoma, Transitional Cell; Glioblastoma; Neoplasms; Triple Negative Breast Neoplasms; Squamous Cell Carcinoma of Head and Neck; Carcinoma, Renal Cell; Stomach Neoplasms; Esophageal Neoplasms; Ovarian Neoplasms; Liver Failure | Details |
| Name | Research Code | Research Phase | Company | Indications | Clinical Trials |
|---|---|---|---|---|---|
| PF-06664178 | PF06664178; PF-06664178 | Pfizer Inc | Details | ||
| BL-M02D1 | Phase 1 Clinical | Baili-Bio (Chengdu) Pharmaceutical Co Ltd, Sichuan Baili Pharmaceutical Co Ltd | Solid tumours; Triple Negative Breast Neoplasms; Digestive System Neoplasms; Breast Neoplasms; Gastrointestinal Neoplasms | Details | |
| BIO-106 | BIO-106 | Phase 2 Clinical | Hangzhou Baikai Biopharmaceutical Co Ltd | Solid tumours; Neoplasms | Details |
| DAC-002 | JS-108; DAC-002 | Phase 1 Clinical | Hangzhou Dac Biotech Company Ltd | Solid tumours; Triple Negative Breast Neoplasms; Small Cell Lung Carcinoma; Neoplasms | Details |
| FDA018 Antibody Drug Conjugate | Phase 2 Clinical | Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co Ltd | Solid tumours; Neoplasms; Triple Negative Breast Neoplasms; Breast Neoplasms | Details | |
| KJ-103 | KJ-103 | Phase 1 Clinical | Kisoji Biotechnology Inc | Rejection of renal transplantation; Solid tumours | Details |
| BAT-8008 | BAT8008; BAT-8008 | Phase 1 Clinical | Bio-Thera Solutions Ltd | Solid tumours; Neoplasms | Details |
| 重组人源化抗Trop2单抗-SN38偶联物 | ESG-401; STI-3258 | Phase 2 Clinical | Shanghai Escugen Biotechnology Co Ltd, Tot Biopharm Co Ltd | Solid tumours; Ovarian Neoplasms; Stomach Neoplasms; Neoplasms; Urinary Bladder Neoplasms; Breast Neoplasms; Colorectal Neoplasms; Lung Neoplasms | Details |
| SKB-264 | SKB-264 | Phase 3 Clinical | Sichuan Kelun Pharmaceutical Co Ltd | Solid tumours; Squamous Cell Carcinoma of Head and Neck; Esophageal Neoplasms; Stomach Neoplasms; Triple Negative Breast Neoplasms; Small Cell Lung Carcinoma; Carcinoma, Ovarian Epithelial; Carcinoma, Transitional Cell; Breast Neoplasms; Endometrial Neoplasms; Adenocarcinoma; Carcinoma, Non-Small-Cell Lung | Details |
| SHR-A1921 | SHR-A1921; SHRA1921 | Phase 1 Clinical | Shanghai Hengrui Pharmaceutical Co Ltd, Suzhou Suncadia Biopharmaceuticals Co Ltd | Solid tumours | Details |
| Datopotamab deruxtecan | Dato-DXd; DS-1062a; DS-1062 | Phase 3 Clinical | Daiichi Sankyo Co Ltd | Solid tumours; Ovarian Neoplasms; Stomach Neoplasms; Triple Negative Breast Neoplasms; Prostatic Neoplasms, Castration-Resistant; Breast Neoplasms; Colorectal Neoplasms; Lung Neoplasms; Endometrial Neoplasms; Carcinoma, Non-Small-Cell Lung; Neoplasm Metastasis | Details |
This web search service is supported by Google Inc.
アクロバイオシステムズの公式アカウント
A-Z
